New Delhi, Sept. 26 -- Indian pharmaceutical exports, including generic drugs, are unlikely to be affected by US President Donald Trump's recent announcement of 100 per cent tariffs on "any branded or patented" drugs imported into the US from October 1. Even though generic drugs are exempt, companies remain uncertain about tariffs due to a US government investigation under Section 232 to determine if pharmaceutical imports threaten national security, according to a report by Moneycontrol.

"The latest tariff announcement is for branded or patented drugs, and not applicable to generics," the news agency quoted Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA).

IPA stands for large domestic pharmaceutical firms with s...